Gelteq Limited Ordinary S... (GELS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
2.71
0.00 (0.00%)
At close: Jan 28, 2025, 1:41 PM
Company Description
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals.
It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products.
The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Gelteq Limited Ordinary Shares
Country | AU |
IPO Date | n/a |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 7 |
CEO | Nathan Jacob Givoni |
Contact Details
Address: 641 Glen Huntly Road Caulfield, VIC AU | |
Website | https://www.gelteq.com |
Stock Details
Ticker Symbol | GELS |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | AUD |
CIK Code | 0001920092 |
CUSIP Number | n/a |
ISIN Number | n/a |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nathan Jacob Givoni | Co-Founder, Chief Executive Officer & Director |
Anthony W. Panther A.C.I.S., AGIA, B.E., C.A., L.L.B., LL.B | Chief Financial Officer |
Craig J. Young | Chief Financial Officer & Company Secretary |
Simon Hayden Szewach | Co-Founder & Executive Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 15, 2024 | 20-F | Filing |
Oct 31, 2024 | NT 20-F | Filing |
Oct 30, 2024 | 6-K | Filing |
Oct 28, 2024 | CERT | Filing |
Oct 22, 2024 | 424B4 | Filing |
Oct 17, 2024 | 8-A12B | Filing |
Sep 25, 2024 | F-1/A | [Amend] Filing |
Sep 12, 2024 | F-1/A | [Amend] Filing |
Jul 15, 2024 | F-1 | Filing |
Jul 15, 2024 | RW | Filing |